Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.76 |
| ▸ | CA1 | P00915 | 1/20 | 0.76 |
| ▸ | CA2 | P00918 | 1/20 | 0.76 |
| ▸ | CA7 | P43166 | 1/20 | 0.76 |
| ▸ | CA9 | Q16790 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227782 | 0.92 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17858266 | 0.90 | CA12 (0.82) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7844094 | 0.86 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15805654 | 0.85 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31513336 | 0.83 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29737158 | 0.82 | NOTUM (0.64) | SMN1; SMN2NOTUMLMNAPKMMAPK1 | |
| SCHEMBL1021359 | 0.82 | NOTUM (0.64) | SMN1; SMN2NOTUMLMNAPKMMAPK1 | |
| SCHEMBL15805636 | 0.82 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2616960 | 0.81 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13624158 | 0.80 | NOTUM (0.66) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025088534-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-05-01 | — | — | WO | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2017096045-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2017096045-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2016097394-A1 | BICYCLIC SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-20040220216-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| WO-2003037252-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1021437-B1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARM IND CO LTD (KR) | 2001-11-14 | — | — | EP | disclosed |
| EP-1021437-A1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2000-07-26 | — | — | EP | disclosed |
| US-5932742-A | CHEMICAL INTERMEDIATE TO ACTIVE ANTITUMOR AGENT | DONG WHA PHARM. IND. CO., LTD. (KR) | 1999-08-03 | — | — | US | disclosed |
| US-5929103-A | ANTICARCINOGENIC AGENTS | DONG WHA PHARM. IND. CO., LTD. (KR) | 1999-07-27 | — | — | US | disclosed |
| WO-1998007719-A1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARM. IND. CO., LTD. (KR) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220216-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CA12 4613/4885CA1 4738/4885CA2 3420/4885 |
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CA12 4613/4885CA1 4738/4885CA2 3420/4885 |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | CA12 4020/4885CA1 4444/4885CA2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.